Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Zai Lab’s Partner, BMS, Meets Endpoints in Trial of KRASG12C Inhibitor for NSCLC

publication date: Apr 1, 2024

Zai Lab highlighted news that its partner Bristol Myers Squibb completed a pivotal Phase III trial showing Krazati® (adagrasib) was effective as a monotherapy in patients with NSCLC that harbors a KRASG12C mutation. Zai Lab added China data to the Phase III trial. In 2021, Zai Lab acquired China rights to adagrasib from Mirati Therapeutics in a $338 million ($60 million upfront) deal. Mirati was bought by BMS in 2023. Zai Lab expects to file an NDA in China later this year for adagrasib as a second or later line therapy in patients with KRASG12C mutated NSCLC. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital